Non-small-cell lung cancer (NSCLC) is malignant cancer accounting for 85% of all lung cancer cases. Over half of people diagnosed with NSCLC die within one year of diagnosis and the 5-year survival is less than 18%. Understanding the need to address this topic, this article outlines current treatment guidelines for early stage (I-II) of NSCLC. Depending on the staging of lung NSCLC, patients are eligible for treatments ranging from surgery to radiation to chemotherapy.
For patients with early-stage NSCLC, surgery followed by adjuvant chemotherapy is the optimal treatment. Treatment of NSCLC remains a challenge for oncologists till date. Surgery Patients with stage I and II NSCLC who are medically fit for conventional surgical resection, lobectomy or greater resection are recommended rather than sublobar resections (wedge or segmentectomy). Sublobar resection is generally considered…
